The experience of Nuclear Medicine Department of G.N.A. Evangelismos on the therapy with 177Lu-PSMA.
The aim of the presented study was to evaluate the efficacy and safety of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) in a hospital clinical setting.
Authors
Fothiadaki Fothiadaki, Vlotzou Vlotzou, Tegos Tegos, Papachristou Papachristou, Bertsekas Bertsekas, Grigorakou Grigorakou, Kalentziou Kalentziou, Rontogianni Rontogianni
View on Pubmed